Targeting TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting

被引：6
|
作者：
Tan, Jiaxiong [1 ,2 ]
Tan, Huo [1 ]
Li, Yangqiu [2 ]
机构：
[1] Guangzhou Med Univ, Affiliated Hosp 5, Dept Hematol, Guangzhou 510700, Peoples R China
[2] Jinan Univ, Inst Hematol, Sch Med, Key Lab Regenerat Med,Minist Educ, Guangzhou 510632, Peoples R China
来源：
EXPERIMENTAL HEMATOLOGY & ONCOLOGY | 2023年 / 12卷 / 01期
基金：
中国国家自然科学基金;
关键词：
TIM-3; Gal-9; Immunotherapy; Hematological malignancies;
D O I：
10.1186/s40164-023-00421-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
T cell immunoglobulin domain and mucin domain-3 (TIM-3) is an important immune checkpoint (IC) protein in cancer immunosuppression that is considered a novel target for immunotherapy. Moreover, TIM-3, an immuno-myeloid regulator, is highly expressed on the cells of several solid tumors and myeloid leukemia stem cells (LSCs). TIM-3 blockade was shown to have dual effects for directly inhibiting leukemia cells and restoring T cell activation. We summarize several of the latest reports on the role of TIM-3 in immunotherapy for hematological malignancies from the 2022 ASH Annual Meeting (ASH2022).
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting
    Guo, Ruiting
    Lu, Wenyi
    Zhang, Yi
    Cao, Xinping
    Jin, Xin
    Zhao, Mingfeng
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [32] BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting
    Zheng, Huijian
    Xian, Huajian
    Zhang, Wenjie
    Lu, Chaoqun
    Pan, Renyao
    Liu, Han
    Xu, Zhenshu
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2025, 18 (01)
  • [33] Novel targeted therapies for immunoglobulin light chain amyloidosis: latest updates from the 2024 ASH annual meeting
    Bu, Qiling
    Zhu, Hong-Hu
    Chen, Wenming
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2025, 18 (01)
  • [34] Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting
    Xubo Gong
    Xin He
    Lin Wang
    Teng Yu
    Weiwei Liu
    Huiying Xu
    Lan Jin
    Xiang Li
    Bin Zhang
    Zhihua Tao
    Wenbin Qian
    Experimental Hematology & Oncology, 13
  • [35] Mechanisms of resistance to CAR-T cell therapy in multiple myeloma: latest updates from the 2024 ASH annual meeting
    Hu, Yuhan
    Hou, Jiangxue
    Jiang, Zhongxing
    Lin, Quande
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2025, 14 (01)
  • [36] Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting
    Gong, Xubo
    He, Xin
    Wang, Lin
    Yu, Teng
    Liu, Weiwei
    Xu, Huiying
    Jin, Lan
    Li, Xiang
    Zhang, Bin
    Tao, Zhihua
    Qian, Wenbin
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2024, 13 (01)
  • [37] Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting
    Huang, Huageng
    Zhang, Wei
    Deng, Xinyi
    Huang, He
    Wang, Zhao
    Hong, Huangming
    Lin, Tongyu
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2024, 13 (01)
  • [38] T-cell immunodeficiency and reconstruction based on TCR rearrangement analysis in hematological malignancy: update from 2011 ASH annual meeting
    Yangqiu Li
    Journal of Hematology & Oncology, 5 (Suppl 1)
  • [39] CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022
    Huang, Ruihao
    Wen, Qin
    Zhang, Xi
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [40] Regimens combining radiation and immunotherapy for cancer: latest updates from 2024 ASCO Annual Meeting
    Liu, Di
    Wu, Leilei
    Xu, Xiaoling
    Yang, Shuangyan
    Liu, Ming
    Hu, Min
    Ren, Shengxiang
    Xu, Yaping
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
12345